Evidence map›Paper›PMID 39844100›Full record

ArticleBMC cancer2025

Personalized optimization of systematic prostate biopsy core number based on mpMRI radiomics features: a large-sample retrospective analysis.

Zhenlin Chen, Zhihao Li, Ruiling Dou, Shaoqin Jiang, Shaoshan Lin, Zequn Lin, Yue Xu, Ciquan Liu, Zijie Zheng, Yewen Lin and 1 more

Abstract read
In one paragraph

Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Zhenlin Chen *Department of Urology, Fujian Union Hospital, Fujian Medical University, Fuzhou, 350001, Fujian Province, China.
Zhihao Li *Center of Reproductive Medicine, Fujian Maternity and Child Health Hospital, Fujian Medical University, Fuzhou, Fujian Province, China.
Ruiling Dou *Department of Urology, Fujian Union Hospital, Fujian Medical University, Fuzhou, 350001, Fujian Province, China.
Shaoqin Jiang *Department of Urology, Fujian Union Hospital, Fujian Medical University, Fuzhou, 350001, Fujian Province, China.
Shaoshan Lin *Department of Urology, Fujian Union Hospital, Fujian Medical University, Fuzhou, 350001, Fujian Province, China.
Zequn LinDepartment of Urology, Fujian Union Hospital, Fujian Medical University, Fuzhou, 350001, Fujian Province, China.
Yue XuDepartment of Urology, Fujian Union Hospital, Fujian Medical University, Fuzhou, 350001, Fujian Province, China.
Ciquan LiuDepartment of Urology, Fujian Union Hospital, Fujian Medical University, Fuzhou, 350001, Fujian Province, China.
Zijie ZhengDepartment of Urology, Fujian Union Hospital, Fujian Medical University, Fuzhou, 350001, Fujian Province, China.
Yewen LinDepartment of Urology, Fujian Union Hospital, Fujian Medical University, Fuzhou, 350001, Fujian Province, China.
Mengqiang LiDepartment of Urology, Fujian Union Hospital, Fujian Medical University, Fuzhou, 350001, Fujian Province, China. limengqiang1125@163.com.

Funding

Fujian Provincial Health Technology Project 2022QNA019Natural Science Foundation of Fujian Province,China 2022J01260Startup Fund for Scientific Research at Fujian Medical University 2018QH1044
6 · The paper itself

Abstract

backgroundProstate cancer (PCa) is definitively diagnosed by systematic prostate biopsy (SBx) with 13 cores. This method, however, can increase the risk of urinary retention, infection and bleeding due to the excessive number of biopsy cores.

methodsWe retrospectively analyzed 622 patients who underwent SBx with prostate multiparametric MRI (mpMRI) from two centers between January 2014 to June 2022. The MRI data were collected to manually segment Regions of Interest (ROI) of the tumor layer by layer. ROI reconstructions were fused to form outline of the volume of interest (VOI), which were exported and applied to subsequent extraction of radiomics features. The t-tests, Mann-Whitney U-tests and chi-squared tests were performed to evaluate the significance of features. The logistic regression was used for calculating the PCa risk score (PCS). The PCS model was trained to optimize the SBx core number, utilizing both mpMRI radiomics and clinical features.

resultsThe predicted number of SBx cores was determined by PCS model. Optimal core numbers of SBx for PCS subgroups 1-5 were calculated as 13, 10, 8, 6, and 6, respectively. Accuracies of predicted core numbers were high: 100%, 95.8%, 91.7%, 90.6%, and 92.7% for PCS subgroups 1-5. Optimized SBx reduced core rate by 41.9%. Leakage rates for PCa and clinically significant PCa were 8.2% and 3.4%, respectively. The optimized SBx also demonstrated high accuracy on the validation set.

conclusionThe optimization PCS model described in this study could therefore effectively reduce the number of systematic biopsy cores obtained from patients with high PCS, especially for biopsy cores far away from suspicious lesions. This method can enhance patient experience without reducing tumor detection rate.

Indexed as

BiopsyProstatic NeoplasmsRadiomicsAgedComputer SimulationHumansMaleMiddle AgedMultiparametric Magnetic Resonance ImagingProstateRetrospective StudiesMpMRIOptimized modelProstate cancerRadiomics featuresSystematic prostate biopsy

Identifiers

PMID39844100
PMCPMC11753051

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.